REG - Oxford Biomedica PLC - Director/PDMR Shareholding <Origin Href="QuoteRef">OXB.L</Origin>

Oxford BioMedicaAnnouncement

16/07/2015 11:13

RNS Number : 3208Q
Oxford Biomedica PLC
16 June 2015
Oxford BioMedica plc Director's Share Purchase
Oxford, UK - 16 June 2015: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, was informed that on 16 June 2015 one of its Directors acquired ordinary shares of 1p each ("Ordinary Shares") as follows:
Interest after purchase
Director / PDMR
Title
Price per share (p)
Number of Ordinary Shares acquired
Number of Ordinary Shares
% of total
issued share capital
Tim Watts
Chief Financial Officer
8.55p
116,931
5,918,934
0.23%
The issued share capital of the Group is 2,568,590,171 1p ordinary shares.
- Ends -
For further information, please contact:
Oxford BioMedica plc:
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer
Tel: +44 (0)1865 783 000
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton
Tel: +44 (0)20 3709 5700
Notes for editors
About Oxford BioMedica
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp. In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RDSBXGDLGGBBGUL